Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

• Published in: PharmacoEconomics Vol. 37; no. 6; pp. 777 - 818
• Main Authors: Hong, Dongzhe, Si, Lei, Jiang, Minghuan, Shao, Hui, Ming, Wai-kit, Zhao, Yingnan, Li, Yan, Shi, Lizheng
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2019; Springer Nature B.V
• Subjects: Antidiabetics; Cost analysis; Cost-Benefit Analysis; Developing countries; Diabetes; Dipeptidyl-Peptidase IV Inhibitors - economics; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Disease; Economics; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Health Administration; Health care expenditures; Health Economics; Health technology assessment; Humans; Hypoglycemia; Hypoglycemic Agents - economics; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Insulin resistance; LDCs; Libraries; Medicine; Medicine & Public Health; Peptides; Pharmacoeconomics and Health Outcomes; Public Health; Quality; Quality of Life Research; Reimbursement; Sensitivity analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors - economics; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Systematic Review
• ISSN: 1170-7690; 1179-2027; 1179-2027
• DOI: 10.1007/s40273-019-00774-9

Objective This study aimed to systematically review cost-effectiveness studies of newer antidiabetic medications. Methods The PubMed/MEDLINE, EMBASE, CINAHL Plus, Cochrane Library–NHS Economic Evaluation Database (Wiley), Cochrane Library–Health Technology Assessment Database (Wiley), Cochrane Library–Database of Abstracts of Reviews of Effects (Wiley), and the Cost-Effectiveness Analysis Registry databases (from 1 January 2000 to 1 June 2018) were searched. The search strategies included the Medical Subject Heading (MeSH) term ‘economics’, and the MeSH entry terms ‘cost’, ‘cost effectiveness’, ‘value’, and ‘cost utility’, as well as all names for GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors. Inclusion criteria included (1) cost-effectiveness studies of the newer antidiabetic medications, including sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors; and (2) full-text publications in English. Two reviewers independently screened the titles, abstracts, and full-text articles to select studies for data extraction. Discrepancies were resolved by discussion and consensus. The quality of reporting cost-effectiveness analyses was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline. Results Among 85 studies selected, 82 clearly stated the types of diabetes model used (e.g. CORE model), and 70 studied used validated diabetes models. Seventy-four (87%) studies were funded by pharmaceutical companies, and 72 (85%) studies were conducted from a payer’s perspective. Seventy-six (89%) studies presented were of good quality (20–24 CHEERS items), and nine were of moderate quality (14–19 items). Thirty studies compared newer antidiabetic medications with insulin, 3 studies compared newer antidiabetic medications with thiazolidinediones (TZDs), 15 studies compared newer antidiabetic medications with sulfonylureas, 40 studies compared new antidiabetic medications with alternative newer antidiabetic medication, and 9 studies compared other antidiabetic agents that were not included above. Newer antidiabetic medications were reported to be cost-effective in 26 of 30 (87%) studies compared with insulin, and 13 of 15 (87%) studies compared with sulfonylureas. Conclusions Most economic evaluations of antidiabetic medications have good reporting quality and use validated diabetes models. The newer antidiabetic medications in most of the reviewed studies were found to be cost effective, compared with insulin, TZDs, and sulfonylureas.